Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Core Insights - The most significant event anticipated for the year is the readout of the RASolute 302 trial, which compares daraxonrasib monotherapy to chemotherapy in previously treated pancreatic cancer patients, expected in the first half of the year [1] Group 1: Clinical Trials - A total of 5 Phase III studies have been initiated, with 4 focused on pancreatic cancer, which are expected to progress in enrollment this year [2] - Previous data from a small cohort indicated response rates for daraxonrasib monotherapy and daraxonrasib plus chemotherapy in first-line pancreatic cancer [2]